



Quick Heal

Investor Presentation

Q2 FY20

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Quick Heal Technologies Ltd. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward-looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward- looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company.

Journey over last two and half decades

Presence in B2C, B2B and B2G segments






Value Proposition



25 Years of Quick Heal Technologies...



...with a Vision & Mission



Vision

To be the trusted Global Leader in
securing the Digital World



Mission

Secure our Customers by providing Innovative,
most preferred and valued Security Solutions,
Services and Knowledge

Protect information and interactions on all
types of networks, devices & things globally

Build a healthy business and organization

...of offering Complete Security Solutions

Segments



Home and SOHO



SME



Government and Enterprise

Platforms



Desktop



Laptop



Mobile



Server



Router



Network



Consumer IoT
Devices

...supported by **Skilled Professionals**



Research & Development Team

Working on identifying new threats and devising innovative solutions and features across retail, enterprise and mobile segments with more than 2 decades of experience



Sales and Marketing Team


Working closely with our customers and Channel Partners to identify new sales prospects, sell solutions and provide after-sales support.



Technical Support Team

Provide efficient multilingual and instant technical support, after sales service and effective guidance to domestic and overseas customers

...with strong Research & Development leading to Innovations



...striving for excellence in customer experience



ISO 20000
certified customer
support process



Remote Access
Support



Onsite support
pan India - Key
Differentiator



Maintain High Levels
of User Satisfaction
and Retention



Multi Channel
Support Services



Multi-lingual end user support in
English, Hindi and several other
major regional Indian languages




Availability of data sheets, product videos
and manuals on website for providing
information on technical specifications,
installation guide, upgrade mechanisms



Release of various articles,
technical papers, quarterly threat
reports and conducting webinars in
the area of security software

...Sales & Distribution to increase Market Share



Established a robust & diversified network and a dynamic ecosystem of Channel Partners in cities & towns across India to reach our end-customers

Strong **internal Sales & Marketing team** work closely with Customers and Channel Partners to identify new sales prospects, sell solutions and provide after-sales support

Disclaimer: Maps not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness

...guided by Experienced Board of Directors



Drives the strategic direction for the company while nurturing a strong leadership team to drive its execution

Dr. KAILASH KATKAR
MD & CEO



Spearheads the creation and subsequent development of the core product technology

Dr. SANJAY KATKAR
Joint MD & CTO



Serves as the MD at Sequoia Capital India. Previously, he worked at Redknee's India subsidiary as the Managing Director

Mr. SHAILESH LAKHANI
Non-Executive Director



Over three decades of experience in corporate finance, legal and litigation, strategy and M&A. Served as the Group CFO of Thermax

Mr. AMITABHA MUKHOPADHYAY
Independent Director



Has 20+ years of diverse experience in building and delivering a range of IT services for customers located across five continents

Ms. PRITI RAO
Independent Director



Serves as Director for RippleWave Equity Advisors LLP. Previously worked at JP Morgan, ICICI Securities and SEBI

Mr. MEHUL SAVLA
Independent Director



Certified bank forensic accounting professional and anti – money laundering expert

Ms. APURVA JOSHI
Independent Director

... and Strong Leadership Team



Dr. Kailash Katkar
MD & CEO

Co-founder of the Company

Has been the driving force in growing Quick Heal Technologies since its inception

A proven leader with a profound proficiency in developing strong client relationships, passion for building outstanding teams and a disciplined focus on operations & execution of strategy



Dr. Sanjay Katkar
Joint MD & CTO

Co-founder of the Company

Leads the global technology strategy & is responsible for the core research & development of the products

Has served as the Director of Association of Anti-Virus Researchers, Asia and is a distinguished speaker at various industry forums

Holds Master's degree in Computer Science from University of Pune



Mr. Nitin Kulkarni
CFO

25+ years of experience in managing different aspects of finance function in IT and Manufacturing Industry

Previously held leadership positions at Tech Mahindra, KPIT, Atlas Copco India and Persistent Systems

A member of the Institute of Chartered Accountants of India

... and Strong Leadership Team



Mr. Nagesh Ayyagari
Vice President – Engineering, R&D

Seasoned technology professional with a reputation for building and inspiring high-performance teams that delivered inline with company

20+ years of experience in leadership positions at Mphasis Software, McAfee, and Oracle

Has management degrees from IIM, Bangalore and ESADE Business School & has done project management from UCB



Mr. Kuldeep Raina, Vice President, Global Enterprise Sales

Responsible for leading the enterprise and government sales strategy and managing the vertical on a global level

Passionate technocrat with a rich flare of selling with tenacity to drive targets in dynamic business environment

19+ years of diverse sales experience including leadership roles in IT Security companies



Mr. Deepak Mishra
Head, Retail Sales

Responsible for enhancing market share and driving channel strategy for the retail brand

19+ years of experience in FMCG, Beverages, Telecom and IT Industries

Has extensive exposure in Sales and Distribution, channel management, and building a robust distribution to drive productivity and profitability

...giving Competitive edge Globally



Quick Heal Global Presence

- India (HO) Quick Heal Technologies Limited
- USA Quick Heal Technologies America Inc
- Kenya Quick Heal Technologies Africa Limited
- UAE Quick Heal Technologies (MENA) FZE
- Japan Quick Heal Japan KK

International Partner Locations

- | | | |
|----------------------------------|-------------|---------------|
| Kenya | Colombia | South Korea |
| Australia | Panama | Sri Lanka |
| Macau | Venezuela | Thailand |
| Malaysia | Japan | Vietnam |
| New Zealand | Gambia | Poland |
| Qatar | Italy | Aruba |
| Singapore | Mauritius | France |
| Democratic Republic Of The Congo | Togo | Germany |
| Nigeria | Uganda | Lithuania |
| South Africa | Zambia | Mexico |
| United Arab Emirates | Bangladesh | Netherlands |
| Iran | Cambodia | Paraguay |
| Jordan | Hong Kong | Spain |
| Oman | Myanmar | United States |
| Turkey | Philippines | |

...certified by Global Agencies

International & ISO Certifications



...trusted by our Customers

"Our products help secure the endpoints, data and networks used by millions of customers"

Some of the industries we cater to:



Manufacturing



BFSI



IT & ITES



Pharma & Healthcare



Automotive



Education



Gems & Jewellery



Hospitality


...creating Specialized workforce at Quick Heal Academy



Popular Courses:

- ✓ Cyber Security and Forensics
- ✓ Cyber Threat Intelligence
- ✓ Malware Analysis & Reverse Engineering
- ✓ Security Operations Centre (SOC)
- ✓ Electronic Crime Scene Investigation

Offerings:



Academy Partners



Savitribai Phule Pune University

Designed 'M-Tech in Information Security' Program for Savitribai Phule Pune University



Maharashtra Cosmopolitan Education Society

The society runs 30 institutes from its ultra modern campaigns located in Maharashtra



Quantum University

MoU with Quantum University for a joint B.Tech (Hons.) with specialization in Cyber Security



Chitkara University

MoU with Chitkara University

Introduced an additional stream in Cyber Security for the four-year Undergraduate program



Gujarat Forensic Sciences University

MoU with Gujarat Forensic Sciences University during Vibrant Gujarat 2017



Deen Dayal Upadhyaya College

MoU with Deen Dayal Upadhyaya College, a constituent college of the University of Delhi

...Awards and Accreditations as testimony to Innovation

2017



- Quick Heal Total Security receives BEST+++ certification from AVLab
- Seqrite Endpoint Security: Best Overall Speed 2017: Silver Award for the Performance Test
- Seqrite Endpoint Security is Approved Corporate Endpoint Protection for Windows by AV-Test
- Approved Windows Security Product for year 2017 by AV-Comparatives
- Seqrite Endpoint Security is ICSAlabs certified product for year 2017

2018



- Seqrite received Best Enterprise IT Security Brand award at 11th NCN innovative product award 2018
- Quick Heal Total Security (Windows) achieved one of the best protection rate in AV-Comparatives test
- Seqrite Endpoint Security certified as 'Approved Corporate Endpoint Protection' for Windows by 'AV-Test'
- Seqrite received best cybersecurity brand award at National Summit on Digital Innovation & Cybersecurity Summit

2019



- Seqrite received the '**Best Performance 2018**' award for its Endpoint Security Solution from **AV-Test Institute** in **Germany**
- Quick Heal granted **Patent for Anti-Ransomware Technology** U.S. Patent No. US20160378988A1
- Quick Heal granted **Patent for its Signatureless Behavior-based Detection Technology** U.S. Patent No. US20170124327A1



Product Offerings




Product Portfolio across Business Segments

Quick Heal

Security Simplified

- Quick Heal Total Security
- Quick Heal Internet Security
- Quick Heal Antivirus Pro
- Quick Heal Total Security For Mac
- Quick Heal Antivirus for Server
- Quick Heal PCTuner 3.0
- Quick Heal Total Security Multi Device
- Quick Heal Home Security
- Quick Heal Total Security for Android





H1 FY20 Revenue Break-up




SEQRITE

- Seqrite Endpoint Security
- Seqrite Endpoint Security Cloud
- Seqrite UTM
- Seqrite mSuite
- Seqrite Encryption
- Seqrite Secure Web Gateway
- Data Loss Prevention (DLP)
- Windows & MAC
- Seqrite Services

Retail / SMB – Drives Scalability



Enterprise Business – Drives Sustainability






Future Opportunities



Turning Problems into Possibilities...

Cybersecurity Predictions - 2019

- Threats to become more **sophisticated** and equipped with advanced **AI-led capabilities**
- Increase in **web skimming attacks**
- Projected rise in **Ransomware** attacks targeting **critical infrastructure**
- An increase in targeted **IoT-based attacks**
- Increase in targeted **cybercrimes** during important public events
- Cryptomining** and **cloud-based attacks** to rise
- Mobile landscape** expected to become more threat-prone in 2019
- Rise in targeted attacks to exploit **supply chain vulnerabilities**
- Attacks on the **financial sector** to increase
- Data protection** to become essential due to **data-centric attacks**



Future Opportunities

- Government** working on strong **data protection regulations**
- Enterprises** are increasingly adopting **security solutions** to combat advanced cyber-threats
- Cyber-attacks** cost the world **\$45 billion** in 2018
- Increase in Mobile Transactions:** According to **RBI data**, **mobile banking transactions** hit **6,200.32 million** in **2018-19**
- Proliferation of **smart devices** will raise **cybersecurity risks**. By **2020**, it is anticipated, the **IoT** may comprise as many as **30 billion devices**
- By **2022**, **6 billion people** will be **vulnerable to cyber-attacks**




Q2FY20 Financial Highlights




Q2FY20 – Quarterly Consolidated Performance Highlights


Revenue** (Rs. mln)




EBITDA (Rs. mln)




Margins (%)



PAT (Rs. mln)



Cash PAT* (Rs. mln)




* Cash PAT = PAT + Depreciation


**As per Ind AS

H1FY20 – Consolidated Performance Highlights


Revenue** (Rs. mln)




EBITDA (Rs. mln)




Margins (%)



PAT (Rs. mln)



Cash PAT* (Rs. mln)




* Cash PAT = PAT + Depreciation


**As per Ind AS

Segment Performance - Revenue Break-up


Retail (Rs. mln)




Enterprise & Govt. (Rs. mln)



Retail (Rs. mln)




Enterprise & Govt. (Rs. mln)




Based on net revenues before adjusting for sales incentives

Segment Performance - Licenses Sold Analysis

Retail (in 000's)



Enterprise & Govt. (in 000's)



Q2FY20 - Profitability Statement

PARTICULARS (Rs. mln)	Standalone			Consolidated		
	Q2FY19	Q2FY20	% change	Q2FY19	Q2FY20	% change
Total Revenue	1,088.56	976.89	-10.26%	1,091.32	985.77	-9.67%
Direct Cost	54.29	33.61		53.73	41.91	
Gross Profit	1,034.27	943.28	-8.80%	1,037.59	943.86	-9.03%
Gross Margin	95.01%	96.56%	+155 bps	95.08%	95.75%	+67 bps
Operating Cost						
Research and Development (R&D)	139.52	137.17		139.52	137.17	
Sales and Marketing (S&M)	160.34	202.31		165.48	207.40	
General Administration (G&A)	131.63	117.78		136.11	121.70	
Total Expenditure	431.49	457.26		441.11	466.27	
EBITDA	602.78	486.02	-19.37%	596.48	477.59	-19.93%
EBITDA Margin	55.37%	49.75%	-562 bps	54.66%	48.45%	-621 bps
Depreciation	60.12	55.25		60.16	55.30	
EBIT	542.66	430.77	-20.62%	536.32	422.29	-21.26%
EBIT Margin	49.85%	44.10%	-576 bps	49.14%	42.84%	- 631 bps
Other Income	86.35	72.95		86.85	73.38	
Profit Before Tax (PBT before exceptional items)	629.01	503.72		623.17	495.67	
Exceptional Item	50.00	0.00		0.00	0.00	
Profit Before Tax (PBT after exceptional items)	579.01	503.72		623.17	495.67	
Tax	201.97	128.05		202.14	128.31	
Profit After Tax (PAT)	377.04	375.67	-0.36%	421.03	367.36	-12.75%
PAT Margin	34.64%	38.46%	+382 bps	38.58%	37.27%	-131 bps

NOTE: Certain figures have been re-grouped wherever necessary

H1FY20 - Profitability Statement

PARTICULARS (Rs. mln)	Standalone			Consolidated		
	H1FY19	H1FY20	% change	H1FY19	H1FY20	% change
Total Revenue	1,616.44	1,548.38	-4.21%	1622.20	1,561.77	-3.73%
Direct Cost	79.77	61.10		76.84	69.12	
Gross Profit	1536.67	1,487.28	-3.21%	1,545.36	1,492.65	-3.41%
Gross Margin	95.07%	96.05%	+98 bps	95.26%	95.57%	+31 bps
Operating Cost						
Research and Development (R&D)	281.83	275.07		281.83	275.07	
Sales and Marketing (S&M)	309.61	334.36		318.98	342.87	
General Administration (G&A)	249.72	261.71		258.83	268.89	
Total Expenditure	841.16	871.14		859.64	886.83	
EBITDA	695.51	616.14	-11.41%	685.72	605.82	-11.65%
EBITDA Margin	43.03%	39.79%	-323 bps	42.27%	38.79%	-348 bps
Depreciation	119.26	106.86		119.38	106.93	
EBIT	576.25	509.28	-11.62%	566.34	498.89	-11.91%
EBIT Margin	35.65%	32.89%	-276 bps	34.91%	31.94%	-297 bps
Other Income	150.10	157.22		150.94	157.84	
Profit Before Tax (PBT before exceptional items)	726.35	666.50		717.28	656.73	
Exceptional Item	50.00	0.00		0.00	0.00	
Profit Before Tax (PBT after exceptional items)	676.35	666.50		717.28	656.73	
Tax	234.90	169.98		235.13	170.40	
Profit After Tax (PAT)	441.45	496.52	+12.47%	482.15	486.33	+0.87%
PAT Margin	27.31%	32.07%	+476 bps	29.72%	31.14%	+142 bps

NOTE: Certain figures have been re-grouped wherever necessary

Q2FY20 - Ratio Analysis

In %	Standalone		Consolidated	
	Q2FY19	Q2FY20	Q2FY19	Q2FY20
Expenses				
Direct Cost / Revenue	4.99%	3.44%	4.92%	4.25%
R&D / Revenue	12.82%	14.04%	12.78%	13.92%
S&M / Revenue	14.73%	20.71%	15.16%	21.04%
G&A / Revenue	12.09%	12.06%	12.47%	12.35%
Total Cost / Revenue	39.64%	46.81%	40.42%	47.30%
Margin				
Gross Margin	95.01%	96.56%	95.08%	95.75%
EBITDA	55.37%	49.75%	54.66%	48.45%
EBIT	49.85%	44.10%	49.14%	42.84%
PBT (Before Exceptional Item)	57.78%	51.56%	57.10%	50.28%
PBT (After Exceptional Item)	53.19%	51.56%	57.10%	50.28%
PAT	34.64%	38.45%	38.58%	37.27%

H1FY20 - Ratio Analysis

In %	Standalone		Consolidated	
	H1FY19	H1FY20	H1FY19	H1FY20
Expenses				
Direct Cost / Revenue	4.93%	3.95%	4.74%	4.43%
R&D / Revenue	17.44%	17.77%	17.37%	17.61%
S&M / Revenue	19.15%	21.59%	19.66%	21.95%
G&A / Revenue	15.45%	16.90%	15.96%	17.22%
Total Cost / Revenue	52.04%	56.26%	52.99%	56.78%
Margin				
Gross Margin	95.07%	96.05%	95.26%	95.57%
EBITDA	43.03%	39.79%	42.27%	38.79%
EBIT	35.65%	32.89%	34.91%	31.94%
PBT (Before Exceptional Item)	44.93%	43.04%	44.22%	42.05%
PBT (After Exceptional Item)	41.84%	43.04%	44.22%	42.05%
PAT	27.31%	32.07%	29.72%	31.14%

Consolidated Balance Sheet

EQUITY AND LIABILITIES (Rs. mln)	Sep 30, 2018	Sep 30, 2019
Share Holder's Funds:		
Equity Share Capital	704.89	642.03
Share application money pending allotment	0.29	0.00
Reserves and Surplus	6,741.95	5,849.78
Total Shareholder Funds	7,447.13	6,491.81
Non-Current Liabilities		
Net employee defined benefit liabilities	14.64	4.64
Other Non Current Liabilities	19.33	19.63
Total Non-Current Liabilities	33.97	24.27
Current Liabilities:		
Trade and Other Payables	395.96	352.53
Other Financial Liabilities	8.40	17.53
Other Current Liabilities	162.00	153.88
Net employee defined benefit liabilities	16.11	18.67
Current tax liabilities (Net)	67.27	38.32
Total Current Liabilities	649.74	580.93
Total Equity & Liabilities	8,130.84	7097.01

ASSETS (Rs mln)	Sep 30, 2018	Sep 30, 2019
Non-Current Assets:		
Property, plant and equipment	1,651.46	1,565.26
Capital work-in-progress	0.00	36.63
Intangible assets	102.19	51.09
Non-current financial assets		
Investments in MF ,Tax-Free Bonds	194.80	320.86
Loan and Security Deposits	3.81	3.81
Bank Balances	3.97	3.89
Deferred tax assets (net)	77.51	66.65
Other non current assets	27.33	85.24
Total Non-Current Assets	2,061.07	2,133.43
Current assets:		
Inventories	60.84	44.57
Investment in Mutual Fund	3,123.02	2,439.87
Trade and other receivables	1,167.22	1,249.94
Bank Balances & Cash and Cash Equivalent	144.74	131.91
Investment in Fixed Deposit	1,485.98	1,012.57
Loan and security deposits	9.00	7.52
Interest accrued on FDR and Tax-Free Bonds	37.54	31.98
Other Current assets	41.43	45.22
Total Current Assets	6,069.77	4,963.58
Total Assets	8,130.84	7097.01

NOTE: Certain figures have been re-grouped wherever necessary

Standalone Balance Sheet


EQUITY AND LIABILITIES (Rs. mln)	Sep 30, 2018	Sep 30, 2019
Share Holder's Funds:		
Equity Share Capital	704.89	642.03
Share application money pending allotment	0.29	0.00
Reserves and Surplus	6,829.49	5,912.19
Total Shareholder Funds	7,534.67	6,554.22
Non-Current Liabilities		
Net employee defined benefit liabilities	14.64	4.64
Other Non Current Liabilities	19.33	19.63
Total Non-Current Liabilities	33.97	24.27
Current Liabilities:		
Trade and Other Payables	392.64	348.17
Other Financial Liabilities	20.05	17.53
Other Current Liabilities	162.08	150.77
Net employee defined benefit liabilities	16.11	18.43
Current tax liabilities (Net)	66.91	37.82
Total Current Liabilities	657.79	572.72
Total Equity & Liabilities	8,226.43	7,151.21

ASSETS (Rs mln)	Sep 30, 2018	Sep 30, 2019
Non-Current Assets:		
Property, plant and equipment	1,651.20	1,564.99
Capital work-in-progress	0.00	36.63
Intangible assets	101.93	50.89
Non-current financial assets		
Investments in MF & Tax-Free Bonds & Subsidiaries	341.96	438.05
Loan and Security Deposits	3.81	3.81
Bank Balances	3.97	3.89
Deferred tax assets (net)	77.51	66.65
Other non current assets	26.87	85.24
Total Non-Current Assets	2,207.25	2,250.15
Current assets:		
Inventories	47.01	40.03
Investment in Mutual Fund	3,123.02	2,439.87
Trade and other receivables	1,168.79	1,248.17
Bank Balances & Cash and Cash Equivalents	107.44	76.89
Investment in Fixed Deposit	1,485.98	1,012.57
Loan and security deposits	8.26	6.84
Interest accrued on FDR and Tax-Free Bonds	37.54	31.98
Other Current assets	41.14	44.71
Total Current Assets	6,019.18	4,901.06
Total Assets	8,226.43	7,151.21


NOTE: Certain figures have been re-grouped wherever necessary

Working Capital Analysis


At the end of September 2018



At the end of March 2019




At the end of September 2019




- Receivable Days = $[(\text{Debtors} / \text{Sales}) \times (183 \text{ days})]$
- Inventory Days = $[(\text{Inventory} / \text{Sales}) \times (183 \text{ days})]$
- Payable Days = $[(\text{Creditor} / \text{Sales}) \times (183 \text{ days})]$

Consolidated Results – Return Ratio Analysis

Return on Capital Employed (%)*



Return on Equity (%)*




RoCE = EBIT / Avg. Capital Employed (Equity + Debt)

Cash Adj. RoCE = EBIT / Avg. Cash Adj. Capital Employed (Equity + Debt – Cash & Cash Equivalents)

ROE = PAT / Avg. Equity

* Calculated on trailing 12 months basis

Shareholding Structure – September 2019



Quick Heal

Security Simplified

CIN No: L72200MH1995PLC091408

Company Secretary

Mr. Srinivas Anasingaraju

cs@quickheal.co.in

+91-20-66813232

www.quickheal.co.in

Chief Financial Officer

Mr. Nitin Kulkarni

Nitin.Kulkarni@quickheal.co.in

+91-20-66813232

www.quickheal.co.in

THANK YOU!
